Candel pushes prostate cancer filing to mid-2027 while cash runway stretches into 2028

Any commercial prospects for Candel Therapeutics' lead candidate in localised prostate cancer now start later. The company said with its third-quarter 2026 results on 12 November that it expects to submit a Biologics License Application for aglatimagene besadenovec in mid-2027. The summary of the announcement does not state the previous target date.

Candel links the new timing to refinement of a test used in the programme and says it is talking to the US Food and Drug Administration about it. The material available does not identify which test is involved or what changes are being discussed, so the effect on the application's content or review is unclear.

The balance sheet gives some room. Candel reported $203.1 million in cash, which it says should fund operations into the second quarter of 2028, a runway that extends past the revised filing window. The company did not provide further financial detail in the information available.

Candel also presented fresh biomarker data at the Society for Immunotherapy of Cancer meeting, covering aglatimagene besadenovec and a second candidate, linoserpaturev. On the supply side, it described validation runs at its contract manufacturer. Those batches are meant to be sold commercially if the product is approved, which suggests manufacturing preparation is continuing during the delay.